Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

headquarters_2_web

Eli Lilly Q2 2016 results surpass estimates

July 27, 2016 Research and Development, Sales and Marketing Eli Lilly, financial report

Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results.  The …
News
money_pills_2

Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals

July 27, 2016 Research and Development phase III, prostate cancer, tokai pharmaceuticals

Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …
News

GSK announces significant post-Brexit UK investment

July 27, 2016 Manufacturing and Production, Research and Development GSK, UK, brexit, investment

GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …
News
ian_campbell

Innovate UK appoints first director of Health and Life Sciences

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ian Campbell, Innovate UK, appointment, health and life sciences

Ian Campbell has been named by Innovate UK as its first director for Health and Life Sciences. Innovate UK is …
Appointment
cq5dam

New drugs to utilise DNA damage response to kill cancer cells

July 26, 2016 Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …
News
celgene_1_02

Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial

July 26, 2016 Research and Development Celgene, Revlimid, lymphoma

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
News

BMS names Fouad Namouni as new oncology development head

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Appointment
gilead-sciences

Gilead lowers full-year guidance as sales and profits down in Q2

July 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results

Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
News
janssen_latest_logo_on_sign_closer

Darzalex receives breakthrough designation in multiple myeloma from FDA

July 26, 2016 Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
News
lab

AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo

July 26, 2016 Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t

AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …
News
sanofi_pasteur_scientist

MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use

July 25, 2016 Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza

Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …
News
merckwindow

400 current and former employees join sexual discrimination lawsuit against MSD

July 25, 2016 Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …
News
abbvie_0

AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C

July 25, 2016 Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C

AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …
News
gilead-sciences

EU recommends PrEP in Gilead’s HIV prevention treatment

July 25, 2016 Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …
News
shire_image

Shire receives positive EU opinion for pancreatic cancer drug

July 25, 2016 Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026